作者: Oliver Cooper , Malin Parmar , Ole Isacson
DOI: 10.1016/B978-0-444-59575-1.00012-0
关键词: Neuroscience 、 Parkinson's disease 、 Cell therapy 、 Biology 、 Cellular differentiation 、 Dopaminergic 、 Induced pluripotent stem cell 、 Embryonic stem cell 、 Somatic cell 、 Transplantation
摘要: Human pluripotent stem cells provide new choices for sources of A9-type dopaminergic (DA) neurons in clinical trials neural transplantation patients with Parkinson's disease (PD). For example, "self" and HLA-matched A9 DA may improve the patient-to-patient variability observed previous using fetal obviate need long-term immunosuppression patient. Normal chromosomal structure minimal somatic mutations are necessary criteria assuring safe reproducible differentiated into PD trials. However, these cell source, application pluripotency assays as to ensure quality becomes less relevant. New more relevant standards control, assurance, function required. We suggest that assurance measures focus upon readouts authentic midbrain neurons, their integration growth vivo assays, functional stability.